Everads Shares First-in-Human Suprachoroidal Delivery Data at EURETINA

Everads Therapy, a biotechnology company based in Tel Aviv, presented the initial clinical results of their first-in-human study at the 24th EURETINA Congress in Barcelona. The study focuses on the safety, feasibility, and tolerability of the Everads Injector for delivering drugs to the back of the eye via the suprachoroidal space.

The study, identified as NCT06314217, is an open-label safety and performance study. It specifically examines the use of the Everads Injector for administering a triamcinolone acetonide suspension to patients suffering from diabetic macular edema (DME). The findings were presented in a talk titled "A Novel Suprachoroidal Delivery Technology: Results from a First in Human Pilot Study – Cohort 1," which is also available as an e-poster and will be published on Everads Therapy's website post-congress.

Dr. Yoreh Barak, the Head of Retina at the Department of Ophthalmology at Rambam Medical Center and the study’s Principal Investigator, emphasized the significance of the results. According to Dr. Barak, the data affirm the effectiveness, ease of use, and tolerability of the Everads Injector for suprachoroidal delivery. He highlighted the potential for physicians to deliver medication non-surgically in an office setting, which could pave the way for more efficient and less invasive treatments for posterior segment eye diseases.

The first cohort of patients was approved by the Ministry of Health, and Everads Therapy is currently enrolling participants for the next cohort. Comprehensive results from the clinical trial are anticipated to be shared at a forthcoming medical congress.

Moshe Weinstein, the CEO of Everads Therapy, expressed excitement over the promising data, which corroborate their technology's clinical viability. These results are expected to support the clinical trial applications of Everads' gene therapy license partners and internal programs. Such validation is crucial for advancing the suprachoroidal delivery of next-generation treatments for retinal diseases.

Everads’ suprachoroidal delivery technology aims to facilitate safe and effective in-office administration of therapies to choroidal and retinal tissues. The technology stands out for its ability to deliver therapy rapidly across the posterior pole, a feature demonstrated in studies by Barak Y et al. and Eclov R et al. at the ARVO 2024 conference. Their research showed the capability of Everads' technology to enable circumferential transduction past the posterior pole to the macular RPE in non-human primates using two AAV serotypes. This rapid distribution to the macular region was also the focus of a recent publication in Translational Vision Science and Technology (TVST).

Everads Therapy is dedicated to optimizing the treatment of retinal diseases through its proprietary suprachoroidal delivery technology. The company aims to overcome the challenges associated with current treatment methods for retinal and macular diseases. Their platform promises to enhance the efficacy and safety of both existing and potential drug therapies. Everads Therapy has established several collaborations in gene therapy, cell therapy, small molecule formulations, and other treatment modalities. Initially spun out from DALI Medical Devices and developed within RAD Biomed, Everads’ foundational technologies were conceptualized by Professor Ygal Rotenstreich from the Goldschleger Eye Institute, with licensing from Sheba Tel Hashomer Medical Center / Sheba Impact.